NKRF in Cardiac Fibroblasts Protects against Cardiac Remodeling Post-Myocardial Infarction via Human Antigen R.
Chenghu GuoWei JiWei YangQiming DengTengfei ZhengZunzhe WangWenhai SuiChungang ZhaiFangpu YuBo XiXiao YuFeng XuQunye ZhangWencheng ZhangJing KongMeng ZhangCheng ZhangPublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Myocardial infarction (MI) remains the leading cause of death worldwide. Cardiac fibroblasts (CFs) are abundant in the heart and are responsible for cardiac repair post-MI. NF-κB-repressing factor (NKRF) plays a significant role in the transcriptional inhibition of various specific genes. However, the NKRF action mechanism in CFs remains unclear in cardiac repair post-MI. This study investigates the NKRF mechanism in cardiac remodeling and dysfunction post-MI by establishing a CF-specific NKRF-knockout (NKRF-CKO) mouse model. NKRF expression is downregulated in CFs in response to pathological cardiac remodeling in vivo and TNF-α in vitro. NKRF-CKO mice demonstrate worse cardiac function and survival and increased infarct size, heart weight, and MMP2 and MMP9 expression post-MI compared with littermates. NKRF inhibits CF migration and invasion in vitro by downregulating MMP2 and MMP9 expression. Mechanistically, NKRF inhibits human antigen R (HuR) transcription by binding to the classical negative regulatory element within the HuR promoter via an NF-κB-dependent mechanism. This decreases HuR-targeted Mmp2 and Mmp9 mRNA stability. This study suggests that NKRF is a therapeutic target for pathological cardiac remodeling.
Keyphrases
- left ventricular
- heart failure
- binding protein
- poor prognosis
- endothelial cells
- mouse model
- transcription factor
- gene expression
- oxidative stress
- type diabetes
- cystic fibrosis
- physical activity
- adipose tissue
- immune response
- skeletal muscle
- long non coding rna
- acute coronary syndrome
- coronary artery disease
- weight loss
- lps induced
- cell proliferation
- metabolic syndrome